Antimicrobial Agents — MCQs

Antimicrobial Agents Indian Medical PG Practice Questions and MCQs

Question 211: Which of the following agents is NOT recommended for the treatment of chronic Hepatitis B?

A. Interferon
B. Lamivudine
C. Adefovir
D. Famciclovir (Correct Answer)

Explanation: **Explanation:** The treatment of chronic Hepatitis B Virus (HBV) focuses on suppressing viral replication to prevent cirrhosis and hepatocellular carcinoma. **Why Famciclovir is the correct answer:** **Famciclovir** is a prodrug of penciclovir, primarily used for Herpes Simplex (HSV) and Varicella-Zoster (VZV) infections. While it possesses some inhibitory activity against the HBV DNA polymerase, clinical trials demonstrated that it is significantly **less effective** than other available agents and carries a high risk of developing resistance. Consequently, it is **not recommended** or FDA-approved for the treatment of chronic Hepatitis B. **Analysis of Incorrect Options:** * **Interferon (Alpha-2b or Pegylated):** These are immunomodulators that enhance the host immune response against HBV. They are first-line options, especially for patients desiring a finite duration of therapy. * **Lamivudine:** A nucleoside reverse transcriptase inhibitor (NRTI). Although it was the first oral anti-HBV drug, its use has declined due to high rates of resistance (YMDD mutation); however, it remains a recognized treatment. * **Adefovir:** A nucleotide analog that inhibits HBV DNA polymerase. While less potent than newer agents like Tenofovir or Entecavir, it is a recognized treatment for chronic HBV. **High-Yield Clinical Pearls for NEET-PG:** * **Drugs of Choice:** Currently, **Tenofovir** (TDF/TAF) and **Entecavir** are the preferred first-line oral agents due to high potency and a high genetic barrier to resistance. * **Mechanism:** Most oral HBV drugs are NRTIs that inhibit the viral **DNA polymerase** (which has reverse transcriptase activity). * **Pregnancy:** Tenofovir is the preferred agent for treating HBV in pregnant women to prevent vertical transmission. * **Side Effect:** Interferon is notorious for causing "flu-like symptoms" and depression.

Question 212: Which one of the following is best associated with Lumefantrine?

A. Antimycobacterial
B. Antifungal
C. Antimalarial (Correct Answer)
D. Antiamoebic

Explanation: **Explanation:** **Lumefantrine** is a long-acting **blood schizonticide** used exclusively as an **antimalarial** agent. It belongs to the amino-alcohol group (chemically related to halofantrine). In modern clinical practice, it is almost always administered as a Fixed-Dose Combination (FDC) with **Artemether**. This combination, known as **ACT (Artemisinin-based Combination Therapy)**, is the WHO-recommended first-line treatment for uncomplicated *Plasmodium falciparum* malaria. **Why the other options are incorrect:** * **Antimycobacterial:** Drugs in this category include Isoniazid, Rifampin, or Bedaquiline, used for TB or Leprosy. Lumefantrine has no activity against *Mycobacterium*. * **Antifungal:** Agents like Fluconazole or Amphotericin B target fungal cell membranes or walls; Lumefantrine does not possess antifungal properties. * **Antiamoebic:** Drugs like Metronidazole or Tinidazole are used for *Entamoeba histolytica*. Lumefantrine is ineffective against intestinal or hepatic amoebiasis. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Lumefantrine inhibits the formation of **β-hematin** by forming a complex with hemin, thereby inhibiting the detoxification of toxic heme into non-toxic hemozoin. * **Pharmacokinetics:** It is highly lipophilic. Its absorption is **significantly increased (up to 16-fold) when taken with a fatty meal**. * **ECG Changes:** Unlike its relative Halofantrine, Lumefantrine has a much lower risk of significant QT prolongation, making it clinically safer. * **Role in ACT:** Artemether provides rapid clearance of parasites, while Lumefantrine provides a sustained effect to prevent recrudescence.

Question 213: Which vitamin is most likely to be deficient in patients on treatment with isoniazid?

A. Vitamin B1
B. Vitamin B2
C. Vitamin B6 (Correct Answer)
D. Vitamin B12

Explanation: **Explanation:** **Mechanism of Deficiency (The "Why"):** Isoniazid (INH) is a structural analog of **Pyridoxine (Vitamin B6)**. It causes deficiency through two primary mechanisms: 1. **Competitive Inhibition:** INH inhibits the enzyme *pyridoxine phosphokinase*, which is essential for converting pyridoxine into its active form, **pyridoxal-5-phosphate (PLP)**. 2. **Increased Excretion:** INH reacts with PLP to form an isoniazid-pyridoxal hydrazone complex, which is rapidly excreted in the urine. Since PLP is a crucial cofactor for neurotransmitter synthesis (like GABA), its deficiency leads to **peripheral neuropathy**, characterized by paresthesia in a "glove and stocking" distribution. **Analysis of Incorrect Options:** * **A. Vitamin B1 (Thiamine):** Deficiency causes Beriberi or Wernicke-Korsakoff syndrome, typically associated with chronic alcoholism, not INH therapy. * **B. Vitamin B2 (Riboflavin):** Deficiency leads to cheilosis, glossitis, and corneal vascularization. It is not affected by anti-tubercular drugs. * **D. Vitamin B12 (Cobalamin):** Deficiency causes megaloblastic anemia and subacute combined degeneration of the spinal cord. Metformin or ileal resection are common causes, but not INH. **Clinical Pearls for NEET-PG:** * **Prophylaxis:** To prevent neuropathy, **10–50 mg/day** of Pyridoxine is co-administered with INH. * **High-Risk Groups:** Alcoholics, diabetics, pregnant women, and malnourished patients are more prone to this deficiency. * **Sideroblastic Anemia:** INH can also cause microcytic anemia because PLP is a cofactor for **ALA synthase**, the rate-limiting enzyme in heme synthesis. * **Metabolism:** INH is metabolized by **N-acetyltransferase**. "Slow acetylators" are at a significantly higher risk of developing B6 deficiency and peripheral neuropathy.

Question 214: Which antibody is used in the treatment of RSV infection?

A. Omalizumab
B. Palivizumab (Correct Answer)
C. Rituximab
D. Daclizumab

Explanation: **Explanation:** **Palivizumab** is the correct answer. It is a humanized monoclonal antibody directed against the **F (fusion) protein** of the Respiratory Syncytial Virus (RSV). By binding to this protein, the antibody prevents the virus from fusing with and entering the host respiratory epithelial cells. It is primarily used for **immunoprophylaxis** in high-risk infants (e.g., those with prematurity, bronchopulmonary dysplasia, or congenital heart disease) to prevent severe lower respiratory tract infections. **Analysis of Incorrect Options:** * **Omalizumab (Option A):** An anti-IgE antibody used in the management of moderate-to-severe persistent allergic asthma and chronic urticaria. It prevents IgE from binding to mast cells and basophils. * **Rituximab (Option C):** A chimeric monoclonal antibody against the **CD20** antigen found on B-cells. It is used in Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), and autoimmune conditions like Rheumatoid Arthritis. * **Daclizumab (Option D):** An IL-2 receptor (CD25) antagonist. It was historically used to prevent renal transplant rejection and in multiple sclerosis (though largely withdrawn due to hepatic toxicity). **High-Yield Clinical Pearls for NEET-PG:** * **Route:** Palivizumab is administered via **intramuscular** injection once a month during the RSV season. * **Target:** Remember the **"F"** in Palivizumab for **F**usion protein. * **Ribavirin:** While Palivizumab is for *prevention*, aerosolized Ribavirin is the antiviral agent used for the *treatment* of severe RSV bronchiolitis in hospitalized children. * **Nirsevimab:** A newer, long-acting monoclonal antibody recently approved for RSV prevention in all infants, which may appear in future exams.

Question 215: Pyronaridine is which type of drug?

A. Antifungal
B. Antimalarial (Correct Answer)
C. Anti-HIV
D. Proton Pump Inhibitor (PPI)

Explanation: **Explanation:** **Pyronaridine** is a potent **antimalarial** drug belonging to the benzonaphthyridine class. It was originally developed in China and is structurally related to amodiaquine. **Why it is the correct answer:** Pyronaridine acts by inhibiting the formation of **β-haematin** (hemozoin), preventing the parasite from detoxifying heme, which leads to parasite death. It is primarily used in a fixed-dose combination with **artesunate** (known as **Pyramax**). This combination is highly effective against both *Plasmodium falciparum* and *Plasmodium vivax*, including multi-drug resistant strains. **Why other options are incorrect:** * **Antifungal:** Common antifungals include azoles (fluconazole) or polyenes (amphotericin B). Pyronaridine has no activity against fungal ergosterol or cell walls. * **Anti-HIV:** These drugs typically include Reverse Transcriptase Inhibitors (Zidovudine) or Protease Inhibitors (Ritonavir). Pyronaridine does not inhibit viral replication. * **Proton Pump Inhibitor (PPI):** These drugs (e.g., Omeprazole, Pantoprazole) inhibit the $H^+/K^+$ ATPase pump in gastric parietal cells. While the name "Pyronaridine" might sound phonetically similar to some PPIs, it has no gastrointestinal acid-suppressing properties. **High-Yield Clinical Pearls for NEET-PG:** * **ACT Combination:** Pyronaridine-Artesunate is the first ACT (Artemisinin-based Combination Therapy) to be approved for both *P. falciparum* and *P. vivax*. * **Efficacy:** It is effective against erythrocytic stages of the parasite. * **Side Effects:** The most notable concern is a transient rise in **liver transaminases** (ALT/AST); therefore, it should be used cautiously in patients with pre-existing liver disease. * **Pharmacokinetics:** It has a long terminal half-life (approx. 13–17 days), providing a period of post-treatment prophylaxis.

Question 216: Which of the following is NOT an anti-Helicobacter pylori drug?

A. Clarithromycin
B. Amoxicillin
C. Metronidazole
D. Tetracycline (Correct Answer)

Explanation: **Explanation:** The treatment of *Helicobacter pylori* infection typically involves a combination of antibiotics and an acid suppressant (PPI). While many antibiotics are effective, the question asks to identify the drug **not** typically considered a primary component of standard regimens in the context of common clinical practice or specific guidelines. **Why Tetracycline is the "Correct" Answer (Contextual Analysis):** In the context of standard NEET-PG pharmacology questions, **Tetracycline** is often the "odd one out" because it is not used in the standard **First-line Triple Therapy**. Triple therapy traditionally consists of a PPI + Clarithromycin + Amoxicillin (or Metronidazole). While Tetracycline *is* used in **Bismuth-based Quadruple Therapy** (PPI + Bismuth + Metronidazole + Tetracycline), it is reserved for second-line treatment or areas with high clarithromycin resistance. In many classic MCQ formats, if a student must choose the "least common" or "non-standard" drug among these options, Tetracycline is selected. **Analysis of Other Options:** * **Clarithromycin (A):** The backbone of first-line triple therapy. It is a macrolide that inhibits protein synthesis. * **Amoxicillin (B):** A penicillin derivative used in first-line therapy due to low resistance rates. It inhibits cell wall synthesis. * **Metronidazole (C):** An imidazole used as an alternative to Amoxicillin in penicillin-allergic patients or as part of quadruple therapy. **High-Yield Clinical Pearls for NEET-PG:** * **First-line Triple Therapy (CAP):** **C**larithromycin, **A**moxicillin, and **P**PI for 10–14 days. * **Sequential Therapy:** 5 days of PPI + Amoxicillin, followed by 5 days of PPI + Clarithromycin + Tinidazole. * **Pylera:** A 3-in-1 capsule containing Bismuth subcitrate, Metronidazole, and Tetracycline. * **Drug of Choice for Penicillin Allergy:** Replace Amoxicillin with Metronidazole.

Question 217: What is the recommended treatment for influenza?

A. Amantadine
B. Ribavarin
C. Interferon
D. Oseltamivir (Correct Answer)

Explanation: **Oseltamivir** is the correct answer because it is the current drug of choice for both the treatment and prophylaxis of **Influenza A and B** [1, 2]. It belongs to the class of **Neuraminidase Inhibitors**. Neuraminidase is an enzyme on the viral surface that cleaves sialic acid receptors, allowing newly formed virions to be released from the host cell. By inhibiting this enzyme, Oseltamivir prevents the spread of the virus within the respiratory tract. **Analysis of Incorrect Options:** * **Amantadine:** This is an M2 ion channel blocker that prevents viral uncoating. It is only effective against Influenza A. However, it is no longer recommended due to widespread high-level resistance and significant CNS side effects [1]. * **Ribavirin:** This is a broad-spectrum antiviral used primarily for Chronic Hepatitis C (in combination) and Respiratory Syncytial Virus (RSV) in children. It is not a first-line treatment for influenza. * **Interferon:** These are endogenous cytokines used in the treatment of Chronic Hepatitis B, Hepatitis C, and certain malignancies (e.g., Hairy Cell Leukemia). They are not used for routine influenza management. **High-Yield Clinical Pearls for NEET-PG:** * **Timing:** Oseltamivir is most effective when started within **48 hours** of symptom onset [2]. * **Route:** Oseltamivir is administered **orally** [2], whereas **Zanamivir** is administered via inhalation (contraindicated in asthma/COPD due to bronchospasm) [1]. * **Newer Agent:** **Baloxavir Marboxil** is a newer, single-dose prodrug that inhibits **cap-dependent endonuclease**, blocking viral RNA synthesis. * **Pregnancy:** Oseltamivir is considered safe and is the preferred agent for pregnant women with influenza.

Question 218: Which antibiotic does not act on tubulin?

A. Bleomycin (Correct Answer)
B. Colchicine
C. Paclitaxel
D. Vincristine

Explanation: The correct answer is **Bleomycin**. The question tests the knowledge of drugs that interact with microtubules (tubulin) versus those that interact directly with DNA. 1. Why Bleomycin is the correct answer: Bleomycin is a cytotoxic antibiotic that acts by binding to DNA and chelating metal ions (iron). This leads to the formation of free radicals (superoxide and hydroxyl radicals), which cause **single and double-strand DNA breaks**, ultimately inhibiting DNA synthesis. It does **not** interact with tubulin or the mitotic spindle [1]. 2. Why the other options are incorrect: * **Colchicine:** An anti-inflammatory drug used in gout that inhibits **tubulin polymerization**, preventing the formation of microtubules. * **Paclitaxel:** A taxane that acts by **stabilizing microtubules** (inhibiting depolymerization), leading to "frozen" spindles and mitotic arrest in the M-phase. * **Vincristine:** A Vinca alkaloid that binds to tubulin and **inhibits polymerization**, preventing spindle formation and causing metaphase arrest. **High-Yield Clinical Pearls for NEET-PG:** * **Bleomycin Toxicity:** The most significant side effect is **Pulmonary Fibrosis** (due to a lack of the enzyme bleomycin hydrolase in the lungs). It is notably "bone marrow sparing." * **Cell Cycle Specificity:** Bleomycin acts specifically in the **G2 phase** [1], whereas microtubule inhibitors (Taxanes and Vincas) act in the **M phase**. * **Griseofulvin:** Another important antimicrobial (antifungal) that acts on tubulin, often tested alongside these options.

Question 219: Which of the following statements about Penicillin G is true?

A. It has a broad spectrum of activity.
B. It can be administered orally.
C. It is used for the treatment of rat bite fever. (Correct Answer)
D. Probenecid, when given with Penicillin G, decreases its duration of action.

Explanation: **Explanation:** **Correct Answer: C. It is used for the treatment of rat bite fever.** Penicillin G (Benzylpenicillin) remains the drug of choice for **Rat-bite fever**, caused by *Streptobacillus moniliformis* or *Spirillum minus*. Despite the emergence of resistance in other bacteria, Penicillin G is highly effective against these specific pathogens, as well as *Treponema pallidum* (Syphilis) and *Neisseria meningitidis*. **Analysis of Incorrect Options:** * **A. Broad spectrum:** Penicillin G is a **narrow-spectrum** antibiotic. It is primarily active against Gram-positive cocci (Streptococci), Gram-positive bacilli (Anthrax, Diphtheria), and certain Gram-negative cocci and spirochetes. It lacks significant activity against most Gram-negative rods. * **B. Administered orally:** Penicillin G is **acid-labile** and is destroyed by gastric acid. Therefore, it must be administered parenterally (IV or IM). Penicillin V (Phenoxymethylpenicillin) is the acid-stable oral alternative. * **D. Probenecid interaction:** Probenecid **increases** the duration of action of Penicillin G. It competes for the organic anion transporter (OAT) in the renal tubules, inhibiting the tubular secretion of penicillin, thereby raising its plasma concentration and half-life. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Penicillin G is the DOC for Syphilis, Gas gangrene (*C. perfringens*), Tetanus, and Actinomycosis. * **Jarisch-Herxheimer Reaction:** A classic adverse effect seen when treating Syphilis with Penicillin G due to the release of endotoxins from dying spirochetes. * **Repository Forms:** Procaine and Benzathine Penicillin are long-acting IM formulations used to maintain sustained therapeutic levels.

Question 220: How does acyclovir inhibit herpes virus replication?

A. Blocks capping of viral mRNA
B. Inhibits reverse transcriptase activity
C. Inhibits viral polymerase activity (Correct Answer)
D. Blocks viral uncoating

Explanation: **Explanation:** Acyclovir is a guanosine analogue that acts as a potent inhibitor of Herpes Simplex Virus (HSV) and Varicella-Zoster Virus (VZV) replication. Its mechanism of action is a classic example of **selective toxicity** involving a three-step phosphorylation process [1]: 1. **Activation:** Acyclovir is first converted to acyclovir monophosphate by the viral enzyme **thymidine kinase** [1], [3]. This ensures the drug is only active in infected cells. 2. **Conversion:** Host cell kinases then convert it into acyclovir triphosphate [1]. 3. **Inhibition:** Acyclovir triphosphate competes with deoxyguanosine triphosphate (dGTP) as a substrate for **viral DNA polymerase** [3], [4]. Once incorporated into the viral DNA chain, it acts as a **chain terminator** because it lacks the 3'-hydroxyl group necessary for further elongation [3]. **Analysis of Incorrect Options:** * **Option A:** Blocking mRNA capping is the mechanism of action for **Ribavirin** (used in HCV and RSV). * **Option B:** Reverse transcriptase inhibition is the hallmark of antiretroviral drugs used for HIV, such as **NRTIs** (e.g., Zidovudine) and **NNRTIs** (e.g., Nevirapine). * **Option D:** Blocking viral uncoating is the mechanism of **Amantadine** and **Rimantadine**, which target the M2 protein of the Influenza A virus. **High-Yield NEET-PG Pearls:** * **Resistance:** Most commonly occurs due to the loss or mutation of the viral **thymidine kinase** enzyme [2]. * **Drug of Choice:** Acyclovir is the gold standard for **Herpes Simplex Encephalitis** (IV) and genital herpes. * **Valacyclovir:** A prodrug of acyclovir with much higher oral bioavailability. * **Side Effects:** Rapid IV infusion can cause **obstructive crystalline nephropathy**; ensure adequate hydration.

Practice by Chapter

Beta-Lactam Antibiotics

Practice Questions

Aminoglycosides

Practice Questions

Macrolides and Ketolides

Practice Questions

Tetracyclines

Practice Questions

Quinolones

Practice Questions

Sulfonamides and Trimethoprim

Practice Questions

Antimycobacterial Drugs

Practice Questions

Antifungal Agents

Practice Questions

Antiviral Drugs

Practice Questions

Antiparasitic Agents

Practice Questions

Principles of Antimicrobial Selection

Practice Questions

Antimicrobial Resistance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free